Patisiran meets Phase III goals in rare disease trial

The APOLLO Phase III study of the investigational RNAi therapeutic patisiran has met the primary and all secondary endpoints in hereditary ATTR amyloidosis patients with polyneuropathy.

This treatment is being developed as part of an alliance between the US RNAi therapeutics specialist Alnylam Pharmaceuticals and Sanofi Genzyme, the specialty care global business unit of French pharma major Sanofi.